Synergic Fabrication of Cabazitaxel-Loaded Dendritic Supramolecular Iron Nanomaterials for the Delivery of Tumor Regression and Magnetic Drug Targeting (MDT) in the Melanoma Tumor Model

Tumour regression efficiency in syngeneic C57BL/6 mice models’ subcutaneous craniofacial melanoma is examined using a magnetically guided delivery system of cabazitaxel (CTX)-loaded dendritic supramolecular iron oxide (IO) nanomaterials. This has a minor impact on hematological, biochemical, and histopathological parameters. The body probably obtained the nanomaterials found in the non-specific spleen, liver, and lungs. On the other hand, tumor-bearing mice had considerably higher localization in magnetically targeted tumors than in non-targeted tumors that were only passively detected. The treated animals had significantly higher tumor iron levels than the control group (Dry organ weight of 25 μg of Fe/mg) and 161 μg of Fe/mg dry organ weight. Due to the high concentration of CTX in the tumor, because of this localization, the tumor underwent significant regression and an arrest in further growth. There was an ~ 88-fold reduction in tumor volume in just 14 days after treatment, from 4794 ± 844 mm 3 (control) to 55 ± 8.3 mm 3 . By the 20th post-treatment day, the tumor was entirely lost, and the patient had a ~ 100% survival rate.